The Medicines and Healthcare products Regulatory Agency (MHRA) has been designated as a WHO-Listed Authority (WLA) by the World Health Organization (WHO).

The MHRA joins Health Canada and Japan’s MHLW/PMDA as newly appointed WLAs announced by the WHO.

The WHO’s WLA framework supports efficient resource use and accelerates access to quality-assured products.

The designation recognises MHRA's commitment to the highest international standards in the regulation of medical products.

Lawrence Tallon, MHRA Chief Executive, commented: "This designation is a proud moment for the MHRA and for the UK. It reflects our unwavering commitment to regulatory excellence, innovation, and global collaboration. As a WHO-Listed Authority, we stand ready to support faster access to life-saving treatments worldwide, while continuing to uphold the highest standards of safety and efficacy."